Potential of nanobiotechnology in the management of glioblastoma multiforme
Glioblastoma: Molecular Mechanisms of Pathogenesis and Current Therapeutic Strategies, Page: 399-419
2010
- 3Citations
- 5Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Glioblastoma multiforme (GBM) is a challenge in management as no cure has been found for this brain cancer. Among new technologies that are being applied to improve management of GBM, nanobiotechnology plays an important role. This chapter reviews the role of new approaches based on nanobiotechnology for improving diagnosis as well as for developing new drugs. The most important challenge is targeted delivery of therapeutics across the blood-brain barrier to the tumor without damaging the normal brain. Integration of diagnosis with therapeutics will facilitate personalized management of GBM.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=79955638157&origin=inward; http://dx.doi.org/10.1007/978-1-4419-0410-2_19; http://link.springer.com/10.1007/978-1-4419-0410-2_19; http://link.springer.com/content/pdf/10.1007/978-1-4419-0410-2_19.pdf; http://www.springerlink.com/index/10.1007/978-1-4419-0410-2_19; http://www.springerlink.com/index/pdf/10.1007/978-1-4419-0410-2_19; https://dx.doi.org/10.1007/978-1-4419-0410-2_19; https://link.springer.com/chapter/10.1007/978-1-4419-0410-2_19
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know